HRP20200521T1 - Kombinacijske terapije za liječenje kemorezistentnih rakova - Google Patents
Kombinacijske terapije za liječenje kemorezistentnih rakova Download PDFInfo
- Publication number
- HRP20200521T1 HRP20200521T1 HRP20200521TT HRP20200521T HRP20200521T1 HR P20200521 T1 HRP20200521 T1 HR P20200521T1 HR P20200521T T HRP20200521T T HR P20200521TT HR P20200521 T HRP20200521 T HR P20200521T HR P20200521 T1 HRP20200521 T1 HR P20200521T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- hypomethylating agent
- dna hypomethylating
- use according
- independently
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 3
- 238000002648 combination therapy Methods 0.000 title 1
- 229940075628 hypomethylating agent Drugs 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 5
- 229960002756 azacitidine Drugs 0.000 claims 5
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- -1 R 21 Chemical compound 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960003603 decitabine Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 claims 1
- GUWXKKAWLCENJA-WGWHJZDNSA-N [(2r,3s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2r,3s,5r)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)C1 GUWXKKAWLCENJA-WGWHJZDNSA-N 0.000 claims 1
- 108010021281 angiotensin I (1-7) Proteins 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (9)
1. DNA hipometilirajuće sredstvo i spoj formule (Id):
[image]
naznačeni time što
R1 je skupina koja ima formulu:
- (CR20R21)m-(CR22R23)n-(CR24R25)o-NR26R27;
R2 je alkil, fluoroalkil, cijano, C2-C6alkenil, C2-C6 alkinil ili heteroalkil, izborno supstituiran sa = 0;
svaki R20, R21, R22, R23, R24 i R25 je samostalno H ili metil;
svaki R26 i R27 je samostalno H, hidroksilalkil ili alkil; i
m, n i o su samostalno cijeli brojevi od 0, 1, 2, 3 ili 4;
ili farmaceutski prihvatljiva sol;
za uporabu u liječenju kemorezistentnog karcinoma odabranog između mijelodisplastičnog sindroma (MDS) ili akutne mijeloidne leukemije (AML).
2. DNA hipometilirajuće sredstvo i spoj za uporabu prema zahtjevu 1, naznačeni time što su R26 i R27 samostalno H ili alkil.
3. DNA hipometilirajuće sredstvo i spoj za uporabu prema zahtjevu 2, naznačeni time što su R26 i R27 samostalno H, metil, etoil, izopropil, propil, butil, izobutil, heksil i heptil.
4. DNA hipometilirajuće sredstvo i spoj za uporabu prema zahtjevima 1 do 3, naznačeni time što R1 je CH2CH2N(CH2CH3)2.
5. DNA hipometilirajuće sredstvo i spoj za uporabu prema zahtjevu 1 ili 2, naznačeni time što R2 je butil.
6. DNA hipometilirajuće sredstvo i spoj za uporabu prema bilo kojem od zahtjeva 1 ili 5, naznačeni time što je rak rezistentan na azacitidin, decitabin, lenalidomid, TXA-127 ili kombinacije istih.
7. DNA hipometilirajuće sredstvo i spoj za uporabu prema bilo kojem od zahtjeva 1-6, naznačeni time što spoj formule (Id) ima strukturu:
[image]
8. DNA hipometilirajuće sredstvo i spoj za uporabu prema bilo kojem od zahtjeva 1-7, naznačeni time što je DNA hipometilirajuće sredstvo 5-azacitidin (azacitidin).
9. DNA hipometilirajuće sredstvo i spoj za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačeni time što DNA hipometilirajuće sredstvo je 5-azacitidin (azacitidin), 5-azadeoksicitidin (decitabin), SGI-110, zebularin ili prokain.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261720346P | 2012-10-30 | 2012-10-30 | |
| PCT/US2013/067607 WO2014070948A1 (en) | 2012-10-30 | 2013-10-30 | Combination therapies |
| EP13851971.5A EP2914254B1 (en) | 2012-10-30 | 2013-10-30 | Combination therapies to treat chemoresistant cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200521T1 true HRP20200521T1 (hr) | 2020-08-07 |
Family
ID=50628036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200521TT HRP20200521T1 (hr) | 2012-10-30 | 2020-03-30 | Kombinacijske terapije za liječenje kemorezistentnih rakova |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150258068A1 (hr) |
| EP (2) | EP2914254B1 (hr) |
| JP (1) | JP6343285B2 (hr) |
| CA (1) | CA2927565C (hr) |
| CY (1) | CY1123043T1 (hr) |
| DK (1) | DK2914254T3 (hr) |
| ES (1) | ES2774296T3 (hr) |
| HR (1) | HRP20200521T1 (hr) |
| HU (1) | HUE048584T2 (hr) |
| LT (1) | LT2914254T (hr) |
| PL (1) | PL2914254T3 (hr) |
| PT (1) | PT2914254T (hr) |
| RS (1) | RS60122B1 (hr) |
| SI (1) | SI2914254T1 (hr) |
| WO (1) | WO2014070948A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0414581C1 (pt) | 2003-09-22 | 2021-05-25 | Mei Pharma Inc | composto, composição farmacêutica compreendendo o referido composto e uso do referido composto |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| US20140031250A1 (en) | 2010-10-07 | 2014-01-30 | David Tsai Ting | Biomarkers of Cancer |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| AR108257A1 (es) * | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP3749330A4 (en) | 2018-02-06 | 2021-11-17 | The General Hospital Corporation | REPEAT RNA AS A BIOMARKER OF TUMOR IMMUNE REACTION |
| EA202191503A1 (ru) * | 2018-11-30 | 2021-11-15 | Мей Фарма, Инк. | Комбинированные терапии для мдс высокого и очень высокого риска |
| JP7115401B2 (ja) | 2019-04-10 | 2022-08-09 | 株式会社デンソー | モータ |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US20100098691A1 (en) * | 2001-01-24 | 2010-04-22 | S'bio Pte Ltd | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| AU2003215112A1 (en) | 2002-02-07 | 2003-09-02 | Axys Pharmaceuticals | Novel bicyclic hydroxamates as inhibitors of histone deacetylase |
| US20040038304A1 (en) | 2002-03-28 | 2004-02-26 | Gala Design, Inc. | Antibody libraries |
| NZ594108A (en) * | 2005-09-08 | 2012-12-21 | S Bio Pte Ltd | Benzimidazole compounds useful as inhibitors of Histone Deacetylase (HDAC) |
| US7700567B2 (en) * | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| JP2012503651A (ja) * | 2008-09-26 | 2012-02-09 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | ３−デアザネプラノシン誘導体 |
-
2013
- 2013-10-30 SI SI201331700T patent/SI2914254T1/sl unknown
- 2013-10-30 LT LTEP13851971.5T patent/LT2914254T/lt unknown
- 2013-10-30 WO PCT/US2013/067607 patent/WO2014070948A1/en active Application Filing
- 2013-10-30 PT PT138519715T patent/PT2914254T/pt unknown
- 2013-10-30 RS RS20200355A patent/RS60122B1/sr unknown
- 2013-10-30 US US14/440,011 patent/US20150258068A1/en not_active Abandoned
- 2013-10-30 JP JP2015539952A patent/JP6343285B2/ja not_active Expired - Fee Related
- 2013-10-30 EP EP13851971.5A patent/EP2914254B1/en active Active
- 2013-10-30 EP EP19206787.4A patent/EP3662911A1/en not_active Withdrawn
- 2013-10-30 HU HUE13851971A patent/HUE048584T2/hu unknown
- 2013-10-30 DK DK13851971.5T patent/DK2914254T3/da active
- 2013-10-30 ES ES13851971T patent/ES2774296T3/es active Active
- 2013-10-30 CA CA2927565A patent/CA2927565C/en active Active
- 2013-10-30 PL PL13851971T patent/PL2914254T3/pl unknown
-
2020
- 2020-03-30 HR HRP20200521TT patent/HRP20200521T1/hr unknown
- 2020-04-06 CY CY20201100321T patent/CY1123043T1/el unknown
- 2020-12-15 US US17/122,991 patent/US20210100775A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6343285B2 (ja) | 2018-06-13 |
| EP2914254A1 (en) | 2015-09-09 |
| CA2927565A1 (en) | 2014-05-08 |
| JP2016501838A (ja) | 2016-01-21 |
| CA2927565C (en) | 2021-05-18 |
| LT2914254T (lt) | 2020-04-27 |
| ES2774296T3 (es) | 2020-07-20 |
| EP3662911A1 (en) | 2020-06-10 |
| US20210100775A1 (en) | 2021-04-08 |
| RS60122B1 (sr) | 2020-05-29 |
| CY1123043T1 (el) | 2021-10-29 |
| EP2914254A4 (en) | 2016-06-29 |
| HUE048584T2 (hu) | 2020-08-28 |
| WO2014070948A1 (en) | 2014-05-08 |
| SI2914254T1 (sl) | 2020-07-31 |
| EP2914254B1 (en) | 2020-01-08 |
| DK2914254T3 (en) | 2020-03-30 |
| PT2914254T (pt) | 2020-04-02 |
| PL2914254T3 (pl) | 2020-09-07 |
| US20150258068A1 (en) | 2015-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200521T1 (hr) | Kombinacijske terapije za liječenje kemorezistentnih rakova | |
| HRP20210212T1 (hr) | Triciklični spoj kao antikancerogeni agensi | |
| JP2016500691A5 (hr) | ||
| NZ706985A (en) | 2’-chloro nucleoside analogs for hcv infection | |
| JP2016501838A5 (hr) | ||
| MX2018003161A (es) | Metodos para tratar infecciones por virus arenaviridae y coronaviridae. | |
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| PH12014502771A1 (en) | Nucleoside phosphoramidate prodrugs | |
| HRP20201023T1 (hr) | Dioksilan analozi uridina za liječenje raka | |
| JP2013507439A5 (hr) | ||
| BR112013012598A2 (pt) | composição de oligossacarídeos para tratar infecções agudas do trato respiratório | |
| CL2013003455A1 (es) | Uso de compuestos inhibidores de sglt-2 derivados de benceno, sustituidos por glucopiranosilo para prevenir, desacelerar la progresion, retrasar o tratar un trastorno metabolico en un pacientes con un agente neuroleptico; uso de la combinacion del inhibidor de sglt2 con un neuroleptico; y composicion farmaceutica de la combinacion. | |
| NZ613370A (en) | Combinations for treating hcv | |
| DK2528930T3 (da) | 4'-azido-nukleosider som anti-hcv-forbindelser | |
| MX2013011915A (es) | Analogos del n-nucleosido de pirimidina 1'-sustituida para tratamiento antiviral. | |
| EP2707379A4 (en) | USE OF PURIFIED 2'-FUCOSYLLACTOSIS, 3-FUCOSYLLACTOSIS AND LACTODIFUCOTETRAOSE AS PREBIOTICS | |
| JP2012092341A5 (hr) | ||
| JP2014507411A5 (hr) | ||
| JP2013507408A5 (hr) | ||
| JP2017061566A5 (hr) | ||
| JP2009536652A5 (hr) | ||
| ZA200704392B (en) | Antibiotic combinations for providing total solution to the treatment of infections | |
| AR090474A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| AR097199A1 (es) | Inhibidores de rorc2 y sus métodos de uso | |
| BRPI0807222A2 (pt) | Análogos de neucleosídeo para tratamento de infecções virais |